MK-3475

pembrolizumab · Merck & Co.

Drug timelines are a Plus or Pro feature.

14 regulatory and trial events tracked for MK-3475, covering 2016-02-24 to 2026-07-01. Get the full timeline:

Most recent: Clinical Trial Update: Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer [Phase 3]

See pricing